Rhythm Pharmaceuticals, Inc.
RYTM
Clasificación en acciones
#2960
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Precio por acción
$90.58
Última sincronización: 2026-10-20
Capitalización bursátil
$6.24B
Cambio (1 día)
2.66%
Cambio (1 año)
-15.46%
País
US
Comercio Rhythm Pharmaceuticals, Inc. (RYTM)
Categoría
Healthcare
Ingresos de Rhythm Pharmaceuticals, Inc. (RYTM)
Ingresos en Jun 2026 TTM: $239.92M
Según los últimos informes financieros de Rhythm Pharmaceuticals, Inc., los ingresos actuales de la empresa (TTM) son $239.92M. En 2023, la empresa obtuvo unos ingresos de $77.43M un aumento con respecto a los ingresos del año 2022, que fueron de $23.64M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Rhythm Pharmaceuticals, Inc. desde 2012 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $239.92M | 84.37% |
| 2024 | $130.13M | 68.06% |
| 2023 | $77.43M | 227.56% |
| 2022 | $23.64M | 649.46% |
| 2021 | $3.15M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 5,161.92% |
US
|
|
| $2.23B | 828.65% |
US
|
|
| $15.74B | 6,462.38% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,409.73% |
NL
|
